Centiva Capital’s Inhibrx INBX Stock Holding History

Centiva Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,739	Closed	-$1.19M	–	2024
2026 Q1	$1.19M	Buy	+17,739	New	+$1.32M	0.01%	541

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Centiva Capital's INBX Position: Q2 2026 in Review

Centiva Capital sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 17,739 shares — an estimated $1.19M sold.

Centiva Capital first reported a position in INBX in Q1 2026 and held it in 1 quarter. The position peaked at $1.19M in Q1 2026. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Centiva Capital reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 17,739 Inhibrx shares in Q2 2026, an estimated $1.19M.
Centiva Capital first reported a position in Inhibrx in Q1 2026 and held it in 1 quarter.
Centiva Capital's Inhibrx position peaked at $1.19M in Q1 2026.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.